Eribulin mesylate (halichondrin B analog E7389) in platinum-sensitive ovarian cancer: A phase II study, CTEP #7431.

5090 Background: Eribulin mesylate is a novel tubulin inhibitor which suppresses microtubule growth without affecting depolymerization, sequestering tubulin into non-functional aggregates. In NIH:OVCAR-3 human epithelial ovarian cancer xenograft models, eribulin increased survival and reduced size and number of metastases, with activity superior to paclitaxel. We sought to determine the frequency of objective response to treatment with eribulin in women with platinum-sensitive recurrent ovarian cancer. Methods: Patients with recurrent, platinum-sensitive (progression-free interval from last platinum > 6 months) epithelial ovarian, fallopian tube, or primary peritoneal cancer who had measurable disease, ≤ 2 prior cytotoxic regimens, ECOG performance status 0-1, and adequate organ function were eligible. Treatment: eribulin 1.4 mg/m2 over 15 minutes by vein days 1 and 8, every 21 days. Response assessed by computed tomography every other cycle. Results: 37 patients enrolled, median age 60 (range 45-77), med...